Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
AlloVir, Inc. is a biopharmaceutical company specializing in allogeneic, off-the-shelf virus-specific T cell (VST) therapies designed to restore immunity in immunocompromised patients at risk of life-threatening viral infections. Its proprietary platform develops multi-virus and single-virus targeted cell therapies for transplant recipients and patients with viral diseases. The company’s business model focuses on developing, manufacturing, and commercializing VST therapies through patented technology and strategic collaborations.
This description was generated via AI from an annual report. Updated about 1 year ago.